Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 2/20 | 0.61 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | LOX | P28300 | 2/20 | 0.56 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HPGDS | O60760 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1767576 | 0.95 | MMP13 (0.67) | MMP13ROCK1KMT2AAURKALMNA | |
| SCHEMBL1767497 | 0.90 | NPC1 (0.60) | KMT2AHTTLMNAHPGDSMN1; SMN2 | |
| SCHEMBL1767521 | 0.90 | HDAC1 (0.62) | MMP13KMT2AHTTLMNASMN1; SMN2 | |
| SCHEMBL1767513 | 0.87 | HTT (0.61) | ROCK1KMT2AHTTLMNASMN1; SMN2 | |
| SCHEMBL1767505 | 0.86 | KDM4E (0.59) | MMP13ROCK1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL2922655 | 0.86 | MMP13 (0.81) | MMP13KMT2AHTTAURKALMNA | |
| SCHEMBL1767448 | 0.83 | KDM5A (0.56) | KMT2AHTTLOXLOXL2LMNA | |
| SCHEMBL1767445 | 0.83 | HPGD (0.64) | KMT2AHTTLMNAHPGDSMN1; SMN2 | |
| SCHEMBL1767434 | 0.82 | HDAC1 (0.60) | KMT2AHTTLMNASMN1; SMN2MEN1 | |
| SCHEMBL1767562 | 0.82 | ALDH1A1 (0.74) | KMT2AHTTLMNASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102119152-B | Organic compounds | NOVARTIS AG | 2014-07-02 | — | — | CN | claimed |
| US-20160289191-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2016-10-06 | — | — | US | disclosed |
| US-20160289191-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2016-10-06 | — | — | US | disclosed |
| US-9187426-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-11-17 | — | — | US | disclosed |
| US-9187426-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-11-17 | — | — | US | disclosed |
| CN-102119152-B | Organic compounds | NOVARTIS AG | 2014-07-02 | — | — | CN | disclosed |
| CN-102119152-A | Organic compounds | NOVARTIS AG | 2011-07-06 | — | — | CN | disclosed |
| US-20110105530-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-05-05 | — | — | US | disclosed |
| US-20110105530-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-05-05 | — | — | US | disclosed |
| WO-2009156484-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105530-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | MMP13 1303/4885ROCK1 4244/4885KMT2A 2098/4885 |
| US-20160289191-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | MMP13 1303/4885ROCK1 4244/4885KMT2A 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.